近日，上市公司又出现一个金融大瓜，引起股市动荡，股民议论纷纷。 上市公司世名科技的第一大股东吕仕铭，被深圳市中级人民法院司法冻结其股票，冻结时间长达3年之久。 令人意外的是，世名科技竟然没有受到这起恶劣事件的影响，其股票价格不仅没有下降，反而还上涨了。 只能说怪事年年有，今年特别多。 1991年，吕仕铭平静的人生出现了重大的转折。 他如愿进入北京师范大学进修研究生课程，毕业后南下香港，顺利进入香港大中集团工作。 从江西到香港，吕仕铭完成了从人民教师到尖端技术人员的蜕变。 1996年，志向远大的吕仕铭放弃了稳定工作，来到昆山创办了世名科技有限公司，开启了自己的创业之旅。 通过多年打拼，世名科技逐渐做大做强，发展成握有20项发明专利，荣获江苏省科学技术奖等多项大奖的企业航母。 2016年，是世名科技创业史上具有里程碑意义的一年。 这一年，世名科技成功在深圳证券交易所上市，作为世名科技的董事长，吕仕铭也因此功成名就，走上人生巅峰。 然而，成也萧何败也萧何。 吕仕铭虽然用新技术打开全世界的销路，成为行业中领头羊，但也因为无限投入技术研发，陷入了严重的资金困境。 原来，新技术新产品需要大量长期巨额资金投入，可不管任何一 ...

Core Viewpoint - Nanjing Puhui Medical Equipment Co., Ltd. is attempting to list on the Hong Kong Stock Exchange amid ongoing financial losses and shareholder cash-outs, contrasting with its previous failed attempt to list on the Shenzhen Stock Exchange four years ago [2] Financial Performance - Puhui Medical's revenue for 2022-2024 was approximately 377 million, 501 million, and 484 million yuan, with a year-on-year decline of 3.47% in 2024 due to reduced sales in key product lines [9][10] - The company reported net losses of 437 million, 159 million, and 442 million yuan for the same period, totaling a cumulative loss of 1.04 billion yuan [9][10] - Operating cash flow was negative in 2023, with net cash flows from operating activities of 373 million, -389 million, and -213 million yuan for 2022-2024 [12] Debt Situation - Puhui Medical's total debt increased from 242 million yuan in 2022 to 525 million yuan in 2024, with short-term debt reaching 525 million yuan in 2024 [12] - As of March 2025, the company had a short-term debt gap of 31.46 million yuan, with cash and cash equivalents only at 11.07 million yuan [12] Shareholder Actions - Shareholders, including Hu Long Jin Cheng Investment Co., Ltd., have been cashing out, with significant share transfers occurring before the IPO application [7][8] - A guarantee agreement was signed between Hu Long Jin Cheng and the chairman, Liu Jinhui, allowing for potential profit-sharing based on future share sales [8] Corporate Governance Concerns - The company has a history of shareholding irregularities, including multiple instances of shareholding by proxy, raising concerns about corporate governance [3][4][5] - As of the latest filing, Liu Jinhui controls 52.5% of the voting rights, indicating concentrated ownership [6] Market Position - Puhui Medical is the second-largest supplier of medical X-ray imaging systems in China, holding a market share of 7.6% in 2023 [13] - Despite current challenges, the company has potential advantages in the orthopedic imaging sector and global expansion opportunities [13]

Group 1 - The article discusses the concepts of "cutting leeks" and "shareholder cashing out," highlighting their essential differences and impacts on the capital market [1][4] - "Cutting leeks" refers to manipulating stock prices and using false information to lure retail investors into buying at high prices, ultimately leading to their losses [5][6] - In contrast, "shareholder cashing out" involves major shareholders legally or through gray methods reducing their stakes to realize wealth, often at the expense of minority investors [6][7] Group 2 - The operators of "cutting leeks" are typically short-term capital players like speculators and quantitative institutions, aiming for quick profits, while "shareholder cashing out" is conducted by major shareholders or actual controllers [7][8] - The legality of these actions differs significantly; "cutting leeks" often involves illegal market manipulation, while "shareholder cashing out" appears compliant but may involve misleading disclosures [7][8] - Victims of "cutting leeks" are primarily retail investors, while "shareholder cashing out" affects not only them but also the company's small shareholders and long-term value [7][8] Group 3 - The article describes complex capital operations that combine both "cutting leeks" and "shareholder cashing out," leading to increased market unfairness and risk [9] - Examples include market value management disguising cashing out and high-premium acquisitions of related party assets, which distort market pricing [9] - Regulatory loopholes in the capital market, such as bulk trading and convertible bonds, can be exploited by unscrupulous shareholders for capital arbitrage [10] Group 4 - The article emphasizes the need for investors to recognize warning signs, especially when shareholder reductions coincide with positive performance forecasts [10] - Investors should scrutinize the true sources of shareholder buy-in funds and their fulfillment records to avoid being misled by false promises [10] - The conclusion stresses that both "cutting leeks" and "shareholder cashing out" ultimately harm small investors and disrupt the normal functioning of the capital market [11]

以下文章来源于镁经 ，作者镁经小组 镁经 . 这是一个美丽又多金的公众号！新消费是我们的领地，擅长商业模式梳理，最爱发掘"美好生活新物种"。 如果您垂直细分、颜值高、易燃易爆炸，是冉冉 升起的网红品牌一枚，欢迎撩我！如果不行，我撩您。 （本公众号为"广州无冕信息技术有限公司"旗下账号。） 来源|镁经 作者|肖汝健 编辑|王大镁 作为A股功能性饮料龙头，东鹏特饮近两年经常因资本运作备受关注。 上市三年，其营收、净利润翻倍增长的同时，股东频繁套现与巨额分红也惹人关注。二股东靠减持累计套现超41亿元，创始人家族累计获得35亿元 分红。 更令人费解的是，这家手握142亿现金类资产的企业，一边大额理财、一边向银行借钱，还引发了不小的争议。 如今，它赴港二次上市的计划浮出水面，市场质疑声浪再起：这究竟是其国际化布局的资本跳板，还是股东套现的"第二通道"？ 01 一边是业绩狂飙，一边是频繁减持 对标红牛起家的东鹏特饮，如今成了名副其实的"造富机器"。 2021年5月上市后，东鹏的市值不断攀升，目前已突破1200亿元。这一市值，让东鹏饮料创始人林木勤以超510亿身家稳坐汕尾首富宝座。 千亿市值背后，是超预期的业绩增长。 数据 ...